AstraZeneca is one of the world’s leading pharmaceutical companies.
AstraZeneca has executed one of the most remarkable strategic transformations in pharmaceutical history, growing from approximately $26 billion in revenues in 2014 to $58.7 billion in 2025, growing at 8% annually. The oncology portfolio is the commercial engine — Tagrisso, Lynparza, Imfinzi, and the landmark Enhertu partnership with Daiichi Sankyo have established AstraZeneca as the only company credibly challenging Roche’s historical dominance in oncology. CEO Pascal Soriot has set a public target of $80 billion in revenues by 2030.
This report provides comprehensive strategic intelligence on AstraZeneca — covering strategic directions, financial performance, SWOT analysis, technological know-how, latest products and services, M&A, marketing tactics, and organization and management.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and key platforms
• Latest products, programs, and innovation pipeline
• M&A activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Strategic Directions
3. Financial Performance
4. SWOT Analysis
5. Technological Know-How
6. Latest Products and Services
7. M&A
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. AstraZeneca — Key Financial Metrics 2023-2025
Table 2. AstraZeneca — Revenue by Therapeutic Area 2023-2025
Table 3. AstraZeneca — Revenue by Geography 2023-2025
Table 4. AstraZeneca — R&D Investment 2023-2025
Table 5. AstraZeneca — SWOT Analysis
Table 6. AstraZeneca — Key Technology Platforms
Table 7. AstraZeneca — Top Products by Revenue 2025
Table 8. AstraZeneca — Late-Stage Pipeline 2025
Table 9. AstraZeneca — M&A Activity 2023-2025
Table 10. AstraZeneca — Key Management
Table 11. AstraZeneca — Strategic Priorities 2025-2030
